Zeria Pharmaceutical Co., Ltd.

As of March 31, 2026, Zeria Pharmaceutical Co., Ltd. carries a market capitalization of 96.75B, placing it among publicly traded companies globally. Its enterprise value stands at 108.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Zeria Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 4, 2026.

As of March 31, 2026, Zeria Pharmaceutical Co., Ltd. has 44.08M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Zeria Pharmaceutical Co., Ltd. maintains a current ratio of 1.48, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Zeria Pharmaceutical Co., Ltd.'s stock has gained approximately 0.30% over the past 52 weeks. The 50-day moving average sits at 2,014.32, while the 200-day moving average is 2,122.25.

As of March 31, 2026, Zeria Pharmaceutical Co., Ltd. holds 27.76B in cash and equivalents against 39.10B in total debt, resulting in a net debt position of 11.34B. Total book value stands at 108.40B, with working capital of 26.94B providing operational flexibility.

Zeria Pharmaceutical Co., Ltd.'s most recent stock split took place on September 26, 2013 with a 10:11 split ratio.